Company Info

Altis Biosystems

CRO, Early R&D

Overview

Altis’s mission is to develop, manufacture and sell innovative services and research tools to accelerate drug development. Their goal is to reduce the time and cost of drug development with in vitro platforms that more accurately reflect native human biology. Altis considers its intestinal platform to be the next generation for in vitro testing during drug development.

Company Services

Regulatory/CertificationsCRO

+ FDA (USA)

Focus Area/Product TypeCRO

Therapeutic CategoriesCRO

Services/CapabilitiesCRO

Contributors

Liz Boazak, Ph.D.

Bailey Zwarycz, Ph.D

Ron Laethem, Ph.D.

Scott Magness, Ph.D.

Nancy Allbritton, Ph.D., M.D.

Company Info

Altis Biosystems

Overview

Company Services

Regulatory/CertificationsCRO

Focus Area/Product TypeCRO

Therapeutic CategoriesCRO

Services/CapabilitiesCRO

Contributors

Contributions

Altis Biosystems Awards New Research Funding to Armed Forces Radiobiology Research Institute

Altis Biosystems Announces New Research Funding Initiative

Accurately Recapitulating Environmental Niches in In Vitro Models of the Intestine

Developing a Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity

Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro

The Power of RepliGut In Vitro Intestinal Stem Cell Models

Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells

How Does Altis Biosystems Envision the Future of the Pharma/Biopharma Industry?

Enhancing Human Gut Tissue Models through Gene Editing

Evaluating Microbiome Therapies with Intestinal Cell Models